Back to search

Peptide record

TPDB25090

Anti-inflammatory Antibacterial Toxicity standard
39 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB25090
Anti-inflammatory Antibacterial Toxicity
Anti-infective peptides Immunity and inflammation peptides Toxicity and safety peptides
Peptipedia
standard
No
A 39-aa standard natural multi-activity (Anti-inflammatory, Antibacterial, and Toxicity) peptide sequence curated from Peptipedia, with an available 3D structural model.
Sequence
RRIRRPRLPRPRVPRPRIPPRIPRPVLPPPRVPFPRFPR
Physicochemical Analysis
C222H375N81O40
ANDCEQGHKMSTWY
P
4818.94
13.51
14
0
10
+14
13.99
-1.223
72.31
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
0
0.00
0
Residue Composition
number
0
A
14
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
3
I
2
L
0
K
0
M
2
F
15
P
0
S
0
T
0
W
0
Y
3
V
Amino Acid Distribution
A: 0 R: 14 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 3 L: 2 K: 0 M: 0 F: 2 P: 15 S: 0 T: 0 W: 0 Y: 0 V: 3
Chemical Descriptors
39
C222H375N81O40
4818.94
13.51
+14
13.99
-1.223
Evidence Records 11 records
Evidence 1 Activity

Activity

MIC
Antibacterial
4 µM

Target

Enterobacter cloacae XDR CI 4172

Source & Reference

NA

Other

ta(sbmA) or delta(mdtM) or delta(ompF) or ML-35p or MDR Ci 1057 or CI 214 (MIC 0.5-8 uM), E. cloacae XDR CI 4172 (MIC 4 uM), A. baumannii XDR CI 2675 (MIC 8 uM), K. pneumoniae ATCC 700603 (MIC 2 uM), P. aeruginosa
Evidence 2 Activity

Activity

MIC
Antibacterial
8 µM

Target

A. baumannii XDR CI 2675

Source & Reference

NA

Other

pF) or ML-35p or MDR Ci 1057 or CI 214 (MIC 0.5-8 uM), E. cloacae XDR CI 4172 (MIC 4 uM), A. baumannii XDR CI 2675 (MIC 8 uM), K. pneumoniae ATCC 700603 (MIC 2 uM), P. aeruginosa ATCC 27853 or PAO1 (MIC 4-8 uM), P.
Evidence 3 Activity

Activity

MIC
Antibacterial
2 µM

Target

Klebsiella pneumoniae ATCC 700603

Source & Reference

NA

Other

4 (MIC 0.5-8 uM), E. cloacae XDR CI 4172 (MIC 4 uM), A. baumannii XDR CI 2675 (MIC 8 uM), K. pneumoniae ATCC 700603 (MIC 2 uM), P. aeruginosa ATCC 27853 or PAO1 (MIC 4-8 uM), P. mirabilis XDR CI (MIC 8 uM), S. aureus
Evidence 4 Activity

Activity

MIC
Antibacterial
4-8 µM

Target

Pseudomonas aeruginosa ATCC 27853 or PAO1

Source & Reference

NA

Other

72 (MIC 4 uM), A. baumannii XDR CI 2675 (MIC 8 uM), K. pneumoniae ATCC 700603 (MIC 2 uM), P. aeruginosa ATCC 27853 or PAO1 (MIC 4-8 uM), P. mirabilis XDR CI (MIC 8 uM), S. aureus ATCC 6538P (MIC 0.25 uM), S-aureus ATCC 29213
Evidence 5 Activity

Activity

MIC
Antibacterial
8 µM

Target

P. mirabilis XDR CI

Source & Reference

NA

Other

uM), K. pneumoniae ATCC 700603 (MIC 2 uM), P. aeruginosa ATCC 27853 or PAO1 (MIC 4-8 uM), P. mirabilis XDR CI (MIC 8 uM), S. aureus ATCC 6538P (MIC 0.25 uM), S-aureus ATCC 29213 or MDR CI 119 (MIC >32 uM), B. s
Evidence 6 Activity

Activity

MIC
Antibacterial
0.25 µM

Target

Staphylococcus aureus ATCC 6538P

Source & Reference

NA

Other

MIC 2 uM), P. aeruginosa ATCC 27853 or PAO1 (MIC 4-8 uM), P. mirabilis XDR CI (MIC 8 uM), S. aureus ATCC 6538P (MIC 0.25 uM), S-aureus ATCC 29213 or MDR CI 119 (MIC >32 uM), B. subtilis B-886 (MIC 16 uM), B. lichen
Evidence 7 Activity

Activity

MIC
Antibacterial
16 µM

Target

B. subtilis B-886

Source & Reference

NA

Other

uM), S. aureus ATCC 6538P (MIC 0.25 uM), S-aureus ATCC 29213 or MDR CI 119 (MIC >32 uM), B. subtilis B-886 (MIC 16 uM), B. licheniformis VKM B511 (MIC 1 uM), and acid-fast M. phlei Ac-1291 (MIC 0.5 uM).
Evidence 8 Activity

Activity

MIC
Antibacterial
1 µM

Target

B. licheniformis VKM B511

Source & Reference

NA

Other

0.25 uM), S-aureus ATCC 29213 or MDR CI 119 (MIC >32 uM), B. subtilis B-886 (MIC 16 uM), B. licheniformis VKM B511 (MIC 1 uM), and acid-fast M. phlei Ac-1291 (MIC 0.5 uM).
Evidence 9 Activity

Activity

MIC
Antibacterial
0.5 µM

Target

M. phlei Ac-1291

Source & Reference

NA

Other

2 uM), B. subtilis B-886 (MIC 16 uM), B. licheniformis VKM B511 (MIC 1 uM), and acid-fast M. phlei Ac-1291 (MIC 0.5 uM).
Evidence 10 Activity

Activity

LC50
Toxicity
100 µM
Cytotoxic
LC50 | 100 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
A Novel Proline-Rich Cathelicidin from the Alpaca Vicugna pacos with Potency to Combat Antibiotic-Resistant Bacteria: Mechanism of Action and the Functional Role of the C-Terminal Region | Membranes (Basel) | 2022
Evidence 11 Activity

Activity

0% Hemolysis
Toxicity
128 µM
Hemolytic Cytotoxic
0% Hemolysis | 128 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A Novel Proline-Rich Cathelicidin from the Alpaca Vicugna pacos with Potency to Combat Antibiotic-Resistant Bacteria: Mechanism of Action and the Functional Role of the C-Terminal Region | Membranes (Basel) | 2022